California State Teachers Retirement System lowered its stake in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 9.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 28,810 shares of the biopharmaceutical company’s stock after selling 3,104 shares during the period. California State Teachers Retirement System owned approximately 0.11% of Intercept Pharmaceuticals worth $1,672,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of ICPT. WFG Advisors LP increased its position in Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 125 shares in the last quarter. IFP Advisors Inc increased its position in Intercept Pharmaceuticals by 90.9% in the 3rd quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 1,182 shares during the period. QCM Cayman Ltd. acquired a new position in Intercept Pharmaceuticals in the 2nd quarter valued at approximately $237,000. Birchview Capital LP acquired a new position in Intercept Pharmaceuticals in the 3rd quarter valued at approximately $250,000. Finally, Oppenheimer & Co. Inc. increased its position in Intercept Pharmaceuticals by 145.1% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 2,833 shares during the period. 75.48% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently weighed in on the stock. Deutsche Bank assumed coverage on shares of Intercept Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $103.00 target price on the stock. Goldman Sachs Group lowered shares of Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a research note on Wednesday, February 7th. ValuEngine lowered shares of Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Oppenheimer reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Monday, January 29th. Finally, Robert W. Baird reissued an “outperform” rating and set a $253.00 price target (down from $332.00) on shares of Intercept Pharmaceuticals in a research report on Thursday, January 25th. Five research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $134.71.
Shares of Intercept Pharmaceuticals Inc (ICPT) traded up $0.42 during trading on Monday, reaching $54.63. 1,022,584 shares of the company’s stock traded hands, compared to its average volume of 1,100,000. Intercept Pharmaceuticals Inc has a twelve month low of $51.05 and a twelve month high of $135.59. The company has a market capitalization of $1,370.00, a price-to-earnings ratio of -3.69 and a beta of -2.13. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15.
COPYRIGHT VIOLATION NOTICE: This article was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/12/california-state-teachers-retirement-system-sells-3104-shares-of-intercept-pharmaceuticals-inc-icpt.html.
Intercept Pharmaceuticals Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.